Project Grant R37CA292056
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$659K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This federal Project Grant award of $336,257.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV MMR-P pancreatic ductal adenocarcinoma. The 3-year award, which runs from September 1, 2024 to August 31, 2027, is granted to The Johns Hopkins University, a private non-profit research institution...
This federal Project Grant award of $589,838.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Johns Hopkins University. The grant supports research to optimize an active mutant KRAS peptide vaccine for the treatment of colorectal cancer (CRC), which is the second leading cause of cancer-related mortality in the U.S. The research aims to develop improved methods for cancer treatment and increase cure rates for CRC patients....
This $835,531 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will fund a research project at The Johns Hopkins University to develop a pooled mutant KRAS-targeted long peptide vaccine combined with anti-PD-1 and anti-CTLA-4 antibodies for patients with stage IV mismatch repair-proficient (MMR-P) pancreatic ductal adenocarcinoma. The project aims to transform healthcare for military service members and the broader...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to Cold Spring Harbor Laboratory to conduct research on a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The research aims to develop prodrug molecules that can selectively degrade the K-RAS(G12C) oncogenic protein while simultaneously releasing cytotoxic natural products to target multiple cancer pathways. Key objectives include determining the...
This $657,776 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a highly tumor-selective pan-RAS inactivator for targeting oncogenic RAS-driven cancers. The award will fund comprehensive characterization and evaluation of this novel agent's anti-tumor activity using a wide range of tumor models. The objective is to develop a tumor-selective, safe, and highly potent pan-RAS inactivator that has high clinical utility for...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $636,046 to the Weill Medical College of Cornell University to conduct research aimed at defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants. The key products and services to be delivered under this 5-year award, which began on November 25, 2024, include: Deciphering how cell lineage impacts the neoplastic transformation and molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $523,480.00 to the Dana-Farber Cancer Institute, Inc. to conduct research aimed at overcoming resistance to KRAS inhibitor therapies in pancreatic ductal adenocarcinoma (PDAC). The research will focus on defining how dysregulated iron metabolism and autophagy-dependent mechanisms contribute to both acute adaptive and long-term acquired resistance to KRAS inhibition in PDAC. The goal is to...
The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
This Project Grant award, with a total funding of $138,742, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The primary awardee, The Johns Hopkins University, will utilize single-cell RNA sequencing data to develop statistical methods for identifying cellular interactions that are altered by combination immunotherapy treatments in pancreatic ductal adenocarcinoma (PDAC). Additionally, the award will support experiments...
The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...